JP5021148B2 - 抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物 - Google Patents

抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物 Download PDF

Info

Publication number
JP5021148B2
JP5021148B2 JP2002532443A JP2002532443A JP5021148B2 JP 5021148 B2 JP5021148 B2 JP 5021148B2 JP 2002532443 A JP2002532443 A JP 2002532443A JP 2002532443 A JP2002532443 A JP 2002532443A JP 5021148 B2 JP5021148 B2 JP 5021148B2
Authority
JP
Japan
Prior art keywords
alkyl
methyl
pharmaceutically acceptable
substituted
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002532443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512281A5 (enExample
JP2004512281A (ja
Inventor
フランシス・ボーリュー
カール・ウレ
マコネン・ベレマ
キウ・ユピン
ヤン・シェジェ
フレッド・シー・ズシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2004512281A publication Critical patent/JP2004512281A/ja
Publication of JP2004512281A5 publication Critical patent/JP2004512281A5/ja
Application granted granted Critical
Publication of JP5021148B2 publication Critical patent/JP5021148B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002532443A 2000-10-03 2001-09-27 抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物 Expired - Fee Related JP5021148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22330400P 2000-10-03 2000-10-03
US60/223,304 2000-10-03
PCT/US2001/042387 WO2002028860A2 (en) 2000-10-03 2001-09-27 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Publications (3)

Publication Number Publication Date
JP2004512281A JP2004512281A (ja) 2004-04-22
JP2004512281A5 JP2004512281A5 (enExample) 2008-11-06
JP5021148B2 true JP5021148B2 (ja) 2012-09-05

Family

ID=22835931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532443A Expired - Fee Related JP5021148B2 (ja) 2000-10-03 2001-09-27 抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物

Country Status (10)

Country Link
US (1) US6960585B2 (enExample)
EP (1) EP1325009B1 (enExample)
JP (1) JP5021148B2 (enExample)
AT (1) ATE319713T1 (enExample)
AU (2) AU1182702A (enExample)
CA (1) CA2424303A1 (enExample)
DE (1) DE60117835T2 (enExample)
ES (1) ES2260300T3 (enExample)
HU (1) HUP0302925A3 (enExample)
WO (1) WO2002028860A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1503673A (zh) 2000-10-26 2004-06-09 �㽭�пؼ����ɷ����޹�˾ 消炎药
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
EP1928887B1 (en) * 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
CN102288753A (zh) * 2011-05-10 2011-12-21 重庆市科学技术研究院 快速检测四环素、金霉素、土霉素与多西环素残留的四联胶体金免疫层析试纸条及其制备方法
BR112016026150B1 (pt) * 2014-05-09 2019-11-05 Pimera, Inc. compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP2020512975A (ja) * 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160097A (en) 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US4225724A (en) * 1977-01-07 1980-09-30 Westwood Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US4236015A (en) 1977-01-07 1980-11-25 Westwood Pharmaceuticals, Inc. 1-(2-Acylaminophenyl)imidazoles
US5196421A (en) 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
US5182386A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
FR2696466B1 (fr) 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
IT1276167B1 (it) 1995-11-24 1997-10-27 Foscama Biomed Chim Farma Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)

Also Published As

Publication number Publication date
ES2260300T3 (es) 2006-11-01
CA2424303A1 (en) 2002-04-11
HUP0302925A2 (hu) 2003-12-29
US20020072523A1 (en) 2002-06-13
WO2002028860A2 (en) 2002-04-11
EP1325009A2 (en) 2003-07-09
WO2002028860A3 (en) 2002-09-06
ATE319713T1 (de) 2006-03-15
HUP0302925A3 (en) 2004-10-28
US6960585B2 (en) 2005-11-01
AU1182702A (en) 2002-04-15
DE60117835T2 (de) 2006-10-19
AU2002211827B2 (en) 2006-12-14
DE60117835D1 (de) 2006-05-04
EP1325009B1 (en) 2006-03-08
JP2004512281A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
EP1325009B1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
JP7721501B2 (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
EP2488519B1 (en) Pyrazolopyridine derivatives as anticancer agent
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
US6933294B2 (en) Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
AU2002211827A1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US6869956B2 (en) Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
AU2002247059B2 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
JPH04235974A (ja) 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
US20180228780A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
EA023045B1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
KR20220012244A (ko) Mrgx2의 억제제로서의 3-아미노-4h-벤조[e][1,2,4]티아디아진 1,1-디옥사이드 유도체
AU2002247059A1 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
CN105473573A (zh) 用作激酶抑制剂的咔唑甲酰胺化合物
JP5937201B2 (ja) ２−アミノ−３−（イミダゾール−２−イル）ピリジン−４−オン誘導体及びｖｅｇｆ受容体キナーゼ阻害剤としてのその使用
CN118684661A (zh) 杂芳基类化合物及其药物组合物、制备方法和用途
CN120092010A (zh) 多环类聚（adp核糖）聚合酶选择性抑制剂
CN121226319A (zh) 烯基取代的哌啶类化合物及其药物组合物、制备方法和用途
JP2023545452A (ja) クリプトスポリジウム症の治療のための化合物及び組成物
JPH06505698A (ja) 新規化合物
KR20190022416A (ko) 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물
CN121226330A (zh) 取代的哌啶类化合物及其药物组合物、制备方法和用途
WO2026096860A1 (en) Tshr inhibitors and methods of use thereof
AU2007200555A1 (en) Methods of treating inflammatory and immune diseases using inhibitors of IKappaB kinase (IKK)
JPS61118386A (ja) トリアゾロキノリン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081021

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081021

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120614

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150622

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees